LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Închisă

SectorSănătate

7.01 -0.85

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

6.96

Maxim

7.15

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.271 49.052
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-29.08% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-35M 349M
Deschiderea anterioară	7.86
Închiderea anterioară	7.01

Sentimentul știrilor

By Acuity

50%

154 / 344 Clasament în Healthcare

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 iun. 2026, 23:36 UTC

Câștiguri

Correction to Oracle Reports Higher 4Q Profit Article

10 iun. 2026, 23:19 UTC

Acțiuni populare

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 iun. 2026, 23:09 UTC

Principalele dinamici ale pieței

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 iun. 2026, 23:04 UTC

Câștiguri

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 iun. 2026, 20:44 UTC

Principalele dinamici ale pieței

Caterpillar Raises Quarterly Dividend 8%

10 iun. 2026, 23:49 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Should Take No Options Off The Table

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 iun. 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 iun. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 iun. 2026, 23:46 UTC

Achiziții, Fuziuni, Preluări

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 iun. 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 iun. 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 iun. 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 iun. 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 iun. 2026, 21:57 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:52 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:35 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:22 UTC

Câștiguri

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 iun. 2026, 20:50 UTC

Market Talk

Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 iun. 2026, 20:39 UTC

Market Talk

Câștiguri

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 iun. 2026, 20:34 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 20:33 UTC

Câștiguri

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Global Equities Roundup: Market Talk

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-29.08% jos

Prognoză pe 12 luni

Medie 5 USD -29.08%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

154 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.